Want to Join Belmore Neidrauer?
Applications can be sent to info@belmorelaw.com
We are experts in intellectual property litigation. We are trial lawyers.
We are appellate lawyers. We know patent law, inside and out.
-
Persuasive Advocacy.
Proven Results.Learn More
News
-
-
Marian Wolanski Recognized by Benchmark Litigation Canada 2026!
Belmore Neidrauer is pleased to announce Marian Wolanski has been recognized as an Intellectual Property Litigation Star by Benchmark Litigation Canada. -
LEXPERT® recognizes Marian Wolanski!
This recognition as one of the Consistently Recommended lawyers for Intellectual Property Litigation is a testament to the depth of talent at Belmore Neidrauer and reflects the firm’s status as a leading law firm for IP litigation in Canada. -
Chambers Patent Litigation 2026
Belmore Neidrauer is proud to be a contributor to Chambers Patent Litigation 2026! The guide provides information on IP rights and granting procedures, initiating a patent infringement lawsuit, patent revocation/cancellation, patent remedies, litigation costs, alternative dispute resolution (ADR), and assignment and licensing of IP rights. -
Belmore Neidrauer Recognized by Managing IP!
Belmore Neidrauer is pleased to announce partner Marian Wolanski has been shortlisted for Practitioner of the Year (Patent Disputes) – Canada at the upcoming 2026 Managing IP Americas Awards! -
The 18th Annual Harold G. Fox Moot
Belmore Neidrauer is pleased to sponsor the Harold G. Fox Moot once again! Marian Wolanski and Megan Pocalyuko are looking forward to volunteering as panel judges this year. Best of luck to all mooters!
Our Team
-
With training in molecular biology, Marian Wolanski has become a leader in patent litigation, advising clients through the complexities of patent disputes.
Our cases
-
Belmore Neidrauer along with co-counsel was presented with the LMG Impact Case of the Year – Canada award for our work on Alexion v Amgen (2025 FC 754).Read more
-
We represented Janssen. This case related to Janssen’s patent covering its blockbuster drug STELARA. The notice of discontinuance was filed October 2, 2025Read more
-
We represented Janssen. This action related to Mitsubishi’s 357 patent covering the diabetes drug INVOKANA. This action was discontinued July 2025.Read more
-
We represented Janssen. This was an action for damages under section 8 of the Patented Medicines Notice of Compliance Regulations relating to abiraterone acetate. The action was discontinued shortly before trial (May 2025).Read more
-
We represented Janssen. This action related to Janssen’s 024 Patent covering the diabetes drug INVOKANA. The action was discontinued in April 2025.Read more
-
Belmore Neidrauer secured another victory in the Federal Court of Appeal for our client Janssen relating to the validity of Janssen’s patent covering INVEGA SUSTENNA®Read more
-
We successfully represented Janssen on another appeal relating to infringement of Janssen’s patent covering INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product for the treatment of schizophrenia.Read more
-
We successfully represented Janssen in the Federal Court of Appeal on this appeal relating to infringement of the patent covering Janssen’s INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product for the treatment of schizophrenia.Read more
-
Belmore Neidrauer has successfully represented Janssen on another appeal, resulting in a decision overturning the Federal Court’s denial of summary judgment.Read more
-
We successfully represented Janssen on Teva’s appeal and Janssen’s cross-appeal in a significant decision relating to the law of inducing patent infringement in Canada. The decision relates to Janssen’s patent covering INVEGA SUSTENNA® (paliperidone ...Read more
-
We successfully represented Janssen in a motion to appeal an order of the Associate Judge which declined, based on relevance, to compel Apotex to answer certain discovery questions related to its ability to supply its generic abiraterone acetate prod...Read more
-
We successfully represented Janssen in a motion to Amend its Statement of Defence in this PMNOC section 8 damages action. The Court agreed that Janssen was allowed to amend its Statement of Defence to raise issues as to Apotex’s ability to supply the...Read more
-
We successfully represented Janssen in this motion brought by Dr. Reddy’s in the context of a PMNOC section 8 damages action. Dr. Reddy’s was seeking to have a question of law determined before trial. The question of law related to whether Janssen co...Read more
-
We successfully represented Janssen in a motion brought by the appellant (Pharmascience) to settle the contents of the appeal book in the context of an appeal from the judgment of the Federal Court in Janssen Inc. v. Pharmascience Inc., 2022 FC 1218 ...Read more
-
This was an application to add an inventor to two patents owned by Alexion Pharmaceuticals. The patents relate to Alexion’s blockbuster drug SOLIRIS. The application was granted, ensuring that the correct inventors are named on the patents relating t...Read more
-
We successfully represented Janssen on these motions seeking non-party discovery in three PMNOC section 8 actions.Each of Apotex, Dr. Reddy’s and Pharmascience resisted, on numerous grounds, non-party discovery for use in these section 8 actions. The...Read more
-
We successfully represented Janssen in defending the validity of the patent relating to Janssen’s INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product used to treat schizophrenia.Read more
-
We successfully represented Janssen in this summary trial in the Federal Court on infringement issues against Apotex in respect of Janssen’s patent covering its important INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product used t...Read more
-
We successfully represented Janssen in this summary trial in the Federal Court on infringement issues against Pharmascience in respect of Janssen’s patent covering its important INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product...Read more
-
We represented Janssen and BTG in these patent infringement actions relating to Janssen’s prostate cancer product ZYTIGA®(abiraterone acetate). We were successful in proving inducing infringement and in resisting the defendants’ attacks based on lack...Read more